Polpharma Biologics S.A., a biotechnology company specializing in the development and manufacturing of biosimilars, has entered into licensing agreements with MS Pharma, a leading biosimilar producer and distributor in the Middle East and North Africa (MENA) region. The partnership covers the commercialization of three biosimilar candidates—vedolizumab (PB016), ocrelizumab (PB018), and guselkumab (PB019)—across the MENA region.

Under the agreements, MS Pharma will oversee registration, marketing, and distribution, while Polpharma Biologics will remain responsible for development, manufacturing, and supply. As part of the collaboration, fill-and-finish activities will be localized within the region at MS Pharma’s biologics manufacturing facility in Saudi Arabia, the first of its kind in MENA.

The three biosimilars address significant unmet needs in gastroenterology, neurology, and dermatology. Vedolizumab, indicated for ulcerative colitis and Crohn’s disease, is a monoclonal antibody that blocks immune cell migration to the gut. Ocrelizumab, used in multiple sclerosis, targets CD20-positive B cells to reduce inflammation and slow disease progression. Guselkumab, indicated for moderate-to-severe plaque psoriasis and psoriatic arthritis, selectively binds to the IL-23 p19 subunit to control immune-driven inflammation.

Commenting on the partnership, Kalle Känd, CEO of MS Pharma, emphasized that expanding the biosimilar portfolio in critical therapeutic areas remains a strategic priority, adding that localized biologics production will further strengthen access in the region. Konstantin Matentzoglu, Supervisory Board Member of Polpharma Biologics Group, highlighted the collaboration’s role in improving treatment accessibility and supporting healthcare system sustainability in MENA.

MS Pharma is a major player in the region, with expertise in generic and biologic medicines, while Polpharma Biologics brings strong EU-based development and manufacturing capabilities. Together, the partnership is positioned to broaden access to affordable, high-quality biologic therapies for patients across MENA.